Show simple item record

dc.contributor.authorGüleç, Mustafa
dc.contributor.authorSelvi, Yavuz
dc.contributor.authorBoysan, Murat
dc.contributor.authorAydın, Adem
dc.contributor.authorBeşiroğlu, Lütfullah
dc.contributor.authorAğargün, Mehmet Yücel
dc.date.accessioned2020-05-28T06:31:30Z
dc.date.available2020-05-28T06:31:30Z
dc.date.issued2011en_US
dc.identifier.citationGüleç, M., Selvi, Y., Boysan, M., Aydın, A., Beşiroğlu, L. ve Ağargün, M. Y. (2011). Ongoing or re-emerging subjective insomnia symptoms after full/partial remission or recovery of major depressive disorder mainly with the selective serotonin reuptake inhibitors and risk of relapse or recurrence: A 52-week follow-up study. Journal of Affective Disorders, 134(1-3), 257-265. https://dx.doi.org/10.1016/j.jad.2011.05.056en_US
dc.identifier.issn0165-0327
dc.identifier.issn1573-2517
dc.identifier.urihttps://hdl.handle.net/20.500.12511/5237
dc.identifier.urihttps://dx.doi.org/10.1016/j.jad.2011.05.056
dc.description.abstractBackground: Many patients who remit fully/partially or recover from an episode of major depression continue to suffer from sleep problems, mainly insomnia. Our study assesses the frequency and types of ongoing or re-emerging subjective insomnia symptoms and their relationship to subsequent depressive relapse or recurrence in a group of full/partial remitters or recoverers.Method: Sixty patients, 18 to 65 years of age, with current MDD defined using DSM-IV-TR criteria were participated in the study. They began a 24-week course of open-label acute plus continuation phase treatment mainly with SSRIs. Maintenance treatment was not planned for not affecting natural relapse or recurrence rates. All participants were evaluated by CGI-S, BDI, HAMD-17, PSQI, and ISI at weeks 0. 4, 12, 24, and 52.Results: Majority of the participants (83.33%) had subjective sleep disturbance, insomnia prior to relapse or recurrence. Repeated measures ANOVA was used to evaluate changes in scores of depression and sleep scales over time between recurred (N =12) and non-recurred groups (N = 48). Differences between means were calculated with post hoc Bonferroni comparison test. The changes in scores of entire clinical scales over time between recurred and non-recurred groups were statistically significant Limitations: The limitations of this study include the use of a relatively small, mostly young female sample and the lack of an objective sleep measure to corroborate self-report scales.Conclusions: Early recognition and treatment of disturbances of the sleep-wake cycle may be important for treatment and prevention of recurrence of depression.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.subjectDepressionen_US
dc.subjectSleepen_US
dc.subjectInsomniaen_US
dc.subjectRemissionen_US
dc.subjectRelapseen_US
dc.subjectRecurrenceen_US
dc.titleOngoing or re-emerging subjective insomnia symptoms after full/partial remission or recovery of major depressive disorder mainly with the selective serotonin reuptake inhibitors and risk of relapse or recurrence: A 52-week follow-up studyen_US
dc.typearticleen_US
dc.relation.ispartofJournal of Affective Disordersen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Ruh Sağlığı ve Hastalıkları Ana Bilim Dalıen_US
dc.identifier.volume134en_US
dc.identifier.issue1-3en_US
dc.identifier.startpage257en_US
dc.identifier.endpage265en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1016/j.jad.2011.05.056en_US
dc.identifier.wosqualityQ1en_US
dc.identifier.scopusqualityQ1en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record